{"name":"GRADE Study Group","slug":"grade-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"DPP-4 inhibitor (sitagliptin)","genericName":"DPP-4 inhibitor (sitagliptin)","slug":"dpp-4-inhibitor-sitagliptin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Sulfonylurea (glimepiride)","genericName":"Sulfonylurea (glimepiride)","slug":"sulfonylurea-glimepiride","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"DPP-4 inhibitor (sitagliptin)","genericName":"DPP-4 inhibitor (sitagliptin)","slug":"dpp-4-inhibitor-sitagliptin","phase":"phase_3","mechanism":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Sulfonylurea (glimepiride)","genericName":"Sulfonylurea (glimepiride)","slug":"sulfonylurea-glimepiride","phase":"phase_3","mechanism":"Glimepiride works by stimulating insulin release from the pancreatic beta cells.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1ZcmVFbUw1bktPRmRHU01pUlN6SnR4d0xocG5GRml4Uzg3TmhJVVdlOTNjNzZ1ZGliejdHOGV4SW1sVTIxVWxMdEdaeTR6ZW1IaER6aWcwbUJ0NHp2ZkZvbjE4OHVoMEVuZklrU2tXaWtlMF9haUNN?oc=5","date":"2026-03-18","type":"trial","source":"EUDA","summary":"Wastewater analysis and drugs — a European multi-city study - EUDA","headline":"Wastewater analysis and drugs — a European multi-city study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNQ2g1dU5ycTJBbHJPNnZIZW9qRktpSFExeGFSRkd3ai1LNVBBZnpCMDY2ZVVtWDdNcXdFdTFzTDlucHVybFFiOTNOSTNwSDYtUWNRTVpPUWZONE5WeWtMSVpEa1N2U1J3Ri1QamJPNWVXU1dpdk4zaUx5QjNmbXNxNXY3aHpDb21RbGdFMWplQ05PSElyTDhoRUd5NFJtNEN3TEhMQlFqd3N2VG9JMzRrN2xsYklpc2s0YVE?oc=5","date":"2026-03-05","type":"trial","source":"Stock Titan","summary":"Microneedle skin cancer patch shows 73% clearance in Medicus trial - Stock Titan","headline":"Microneedle skin cancer patch shows 73% clearance in Medicus trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-17","type":"trial","source":"India Today","summary":"Hidden dangers in your protein powder? New study exposes alarming facts - India Today","headline":"Hidden dangers in your protein powder? New study exposes alarming facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNRjNrdDZ2NFJZZHI5Q1hFZm1XVVg4OExlM1Vneml6Uk9GZmhkNUhUZXROQV9VUnNYMGZ6NERtQmgwVEQ1dmhrVXFqRHNoRHpIZmVNcTc3OHpRbEdkb0todnhLY1R4SlZTcmxoam1MNjJZZDRZQjJjNU53VUxsSzNLaDRMRF8yQ01lVjhCaUIwTHdMb3VZcXdwVlpBbw?oc=5","date":"2025-11-13","type":"pipeline","source":"Cannabis & Tech Today","summary":"How Big Pharma Plans to Destroy the Cannabis Industry As We Know It - Cannabis & Tech Today","headline":"How Big Pharma Plans to Destroy the Cannabis Industry As We Know It - Cannabis & Tech Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxQcE9lcjNlckN3N2Eyd005NGVRYkgzeWlodlpoUGp1Q05qMFc1OG9MZkN2N21hTnpGVDFWVlRpUVZWc3pRd0JaWXhqVVlXN2JTclR0VmJfaE83dmItOFp4MXpqZFRqQk5kd0d5cWFFbjg5aF92dFR4OUJ2aVJVYmE3WEZZSnJuU29aVzI3NXZsRjNnUTJHVm5rZVhucVNPeW53R1ZXSEViX19XckJfM3JzdWE3ck5xRm5MT2ZhZjZXZ1NsSzN1VWJic3JDdHBUZk1ZUUlHNlAzOTZ6N2lWUkowUk5QMnBHeElXQ1ctUmpncTVRZnA0el9uQm1qS3ZSMUgtZFVRTEIwOURqSEJsVjJKdXpMTXA2VkU5RzBaTHpaSEQwdG43WjNobEprUDNYM3VnZnU3U3JsV1dBRk1QY3ltVk5pUURzZFp6aGxKR1R2cVlfMlJLUmVZ?oc=5","date":"2025-10-07","type":"trial","source":"Finansavisen","summary":"Cinclus Pharma doses first patient in Phase III study evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease - Finansavisen","headline":"Cinclus Pharma doses first patient in Phase III study evaluating linaprazan glurate for the treatment of erosive gastroe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNYWk5d2VfYmkzemlORmI5bVpoS3Jhc0k4a2xDcmJVdnJQQ0p0NDUwZWlTLTBUSnlBaFJhaElTLWIyTkZUOVltVVIyc0xDT1lpTV91YVhoMEt6QnpwMUFxR0tLNzRIbWtJQXh0ZTVpdENIUlFuLTlubENicmFsalpoWjBUM2ZKUQ?oc=5","date":"2025-09-17","type":"pipeline","source":"Fierce Pharma","summary":"AstraZeneca's Fasenra comes up short again in COPD as injectable Saphnelo makes grade in lupus - Fierce Pharma","headline":"AstraZeneca's Fasenra comes up short again in COPD as injectable Saphnelo makes grade in lupus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxORG9OdlN3OFJNVXlhb0FzZDJ2QWhfS0ZpMEZybjI1YjdiMnNJMUlrZ3NTamJ0ZGl4a0RZbHg3eG9VMXJJUzU1M3QtWmRnRW1BWGRGNzJLUGw3anIyOXJSYVBGWElJZk01UnBxWEU5RW16bEVkUWFCY2JuRXZrSU1wRFdCVm5hWWgtc1cwNFhxWExhd19UWlBrWmQ5QQ?oc=5","date":"2025-08-07","type":"trial","source":"BioPharma Dive","summary":"Lilly shares fall as obesity pill misses expectations in key trial - BioPharma Dive","headline":"Lilly shares fall as obesity pill misses expectations in key trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNaEg5NzlsVWVZeVFZamJYMzRmZlZTYWRCU05USWRMTUJ2S1BvVTlYb3ZfMzRnbmJuSTdHMkdjV2pTZHB1T2dMdWxRY1hRLWR3X2Q3YXlrYmhZYVBwOEpkb1ZkU2V0bEZINEFWRm5pc0tENk1kRGFjUVNVaXJKX2g1QVM2eTlTaERCMG1EcGZubmVGQl9fa2NuTWQtYnV0b21GeXZ1Z0pZNlVNcTlVbTVkRGhORlRlZFR2dWx2RzhZUHJ4cHVwbm9nWmRzU3dzTldnZk4tTlI1dw?oc=5","date":"2025-07-02","type":"regulatory","source":"Journal of Hematology Oncology Pharmacy","summary":"Incidence of Febrile Neutropenia in Patients With Grade 3 or 4 Neutropenia Who Are Receiving Palbociclib - Journal of Hematology Oncology Pharmacy","headline":"Incidence of Febrile Neutropenia in Patients With Grade 3 or 4 Neutropenia Who Are Receiving Palbociclib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNaFhCNHVvSmZNblhzUDE3S2txT3lrNEYySTF2S2hqZ3RQTTMzdFpsbm44cVZhblMyNFhsTnlKSms0SGwxVTRPWVBKZUJZRWxaazdGLXRTVWpDalVNa21JbmYzU3BYSkk2ejc4Tzh6ZGx4U2IxX2xzWGhfSjlVdnAzdm9wTF9WejJNSG9jR1M0WTRVU2hYeXFqdFA1MUtaakVIYmxaeVF6aHJlMlpvc051Wl9PUVptSFVrMDBSOUZ3TmthUko2NHd6R01n?oc=5","date":"2025-06-16","type":"pipeline","source":"IQVIA","summary":"Measure Pharma Sales Effectiveness: Understanding the BrandImpact® Score - IQVIA","headline":"Measure Pharma Sales Effectiveness: Understanding the BrandImpact® Score","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQWWJ5bVFTaDk5NXJnNEJaRE1ZSlVDSXJCYzM5UUR2UlZYWTh1dF9XM3FvdEhKZVJUeEFnZFVFMEZOa2dianZQUjNjQVBvLVdnZWtpZnptYWh0ZkdHZU1mRHZvT2lsVkk5WkJ3TGdpUmNjb1NxeVhVdHdnc3lTVllCRXpoekIxVXFTRzBiWnpKRnVlRTBlaTJLenQ4R0pMdw?oc=5","date":"2025-06-11","type":"trial","source":"Medscape","summary":"Study Shows Safety of Pharma-Grade CBD for Myocarditis - Medscape","headline":"Study Shows Safety of Pharma-Grade CBD for Myocarditis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOaFozWDZDZjV0WHFkVEM1OXRsZVlxVTBCYlFsVDhCNnFyMFRTS05Qb2VpU1d1NnVzcVl5VENfVzhFWmV4eGRldGJXV3pmZDMzQXNhcXZRaEIzS2xVbXZqNHNFU1NoYTBCWE9JZldDa0Q1Vm92RGlFN3Fia09FRU9SSDQwWFpsVl9MX09hLWVmSzd1YjlYaWow?oc=5","date":"2025-04-25","type":"pipeline","source":"Future Market Insights","summary":"Pharmaceutical Grade Sodium Bicarbonate Market Trends & Forecast, 2025-2035 - Future Market Insights","headline":"Pharmaceutical Grade Sodium Bicarbonate Market Trends & Forecast, 2025-2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBpSnV2dUFaaWpNZmpRYnJMUk5ycEtaWnQ0aEhaakdtQkp3cUxqTVh2ZUswVUdBZmZUYXB4VVJlS3ZPU3ZkcFRMbFJYWGxEZXJmUDJETE41S2Itb18zWVlN?oc=5","date":"2024-06-12","type":"trial","source":"Nature","summary":"Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months - Nature","headline":"Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}